Literature DB >> 18000807

Androgen-mediated cholesterol metabolism in LNCaP and PC-3 cell lines is regulated through two different isoforms of acyl-coenzyme A:Cholesterol Acyltransferase (ACAT).

Jennifer A Locke1, Kishor M Wasan, Colleen C Nelson, Emma S Guns, Carlos G Leon.   

Abstract

BACKGROUND: The objective of this work was to determine the effect of an androgen agonist, R1881, on intracellular cholesterol synthesis and esterification in androgen-sensitive (AS) prostate cancer (LNCaP) cells.
METHODS: We investigated the activity and expression of cholesterol metabolism enzymes, HMG-CoA-reductase and ACAT in the LNCaP and PC-3 (androgen-independent control) models.
RESULTS: Microsomal PC-3 HMG-CoA-reductase activity was increased with R1881 despite having similar cholesterol levels while increased cholesterol levels in microsomes from LNCaPs treated with R1881 (L+) were associated with increased HMG-CoA reductase activity. Increased intracellular cholesteryl esters (CE) found in (L+) were not associated with an increased ACAT1 activity. There was no effect from androgen treatment on ACAT1 protein expression in theses cells; however, ACAT2 expression was induced upon R1881 treatment. In contrast, we found an increase in the in vitro ACAT1 activity in PC-3 cells treated with androgen (P+). Only ACAT1 expression was induced in P+. We further assessed the expression of STAT1 alpha, a transcriptional activator that modulates ACAT1 expression. STAT1 alpha expression and phosphorylation were induced in P+. To determine the role of the AR on ACAT1 expression and esterification, we treated PC-3 cells overexpressing the androgen receptor with R1881 (PAR+). AR expression was decreased in PAR+ cells; ACAT1 protein expression and cholesterol ester levels were also decreased, however, ACAT2 remained unchanged. STAT1 alpha expression was decreased in PAR+.
CONCLUSIONS: Overall, these findings support the importance of cholesterol metabolism regulation within prostate cancer cells and unravel a novel role for STAT1 alpha in prostate cancer metabolism. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18000807     DOI: 10.1002/pros.20674

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  16 in total

1.  Exosomes as biomarker enriched microvesicles: characterization of exosomal proteins derived from a panel of prostate cell lines with distinct AR phenotypes.

Authors:  Elham Hosseini-Beheshti; Steven Pham; Hans Adomat; Na Li; Emma S Tomlinson Guns
Journal:  Mol Cell Proteomics       Date:  2012-06-21       Impact factor: 5.911

Review 2.  Cholesterol as a potential target for castration-resistant prostate cancer.

Authors:  Alexis L Twiddy; Carlos G Leon; Kishor M Wasan
Journal:  Pharm Res       Date:  2010-08-04       Impact factor: 4.200

3.  Sterol O-Acyltransferase 2-Driven Cholesterol Esterification Opposes Liver X Receptor-Stimulated Fecal Neutral Sterol Loss.

Authors:  Manya Warrier; Jun Zhang; Kanwardeep Bura; Kathryn Kelley; Martha D Wilson; Lawrence L Rudel; J Mark Brown
Journal:  Lipids       Date:  2016-01-04       Impact factor: 1.880

Review 4.  Androgen action and metabolism in prostate cancer.

Authors:  Sean M Green; Elahe A Mostaghel; Peter S Nelson
Journal:  Mol Cell Endocrinol       Date:  2012-03-20       Impact factor: 4.102

5.  Quantitative proteomic profiling of prostate cancer reveals a role for miR-128 in prostate cancer.

Authors:  Amjad P Khan; Laila M Poisson; Vadiraja B Bhat; Damian Fermin; Rong Zhao; Shanker Kalyana-Sundaram; George Michailidis; Alexey I Nesvizhskii; Gilbert S Omenn; Arul M Chinnaiyan; Arun Sreekumar
Journal:  Mol Cell Proteomics       Date:  2009-11-09       Impact factor: 5.911

6.  Quantitative proteomics reveals that enzymes of the ketogenic pathway are associated with prostate cancer progression.

Authors:  Punit Saraon; Daniela Cretu; Natasha Musrap; George S Karagiannis; Ihor Batruch; Andrei P Drabovich; Theodorus van der Kwast; Atsushi Mizokami; Colm Morrissey; Keith Jarvi; Eleftherios P Diamandis
Journal:  Mol Cell Proteomics       Date:  2013-02-26       Impact factor: 5.911

7.  Diagnostic biomarkers for renal cell carcinoma: selection using novel bioinformatics systems for microarray data analysis.

Authors:  Adeboye O Osunkoya; Qiqin Yin-Goen; John H Phan; Richard A Moffitt; Todd H Stokes; May D Wang; Andrew N Young
Journal:  Hum Pathol       Date:  2009-08-19       Impact factor: 3.466

Review 8.  Classical and Non-Classical Roles for Pre-Receptor Control of DHT Metabolism in Prostate Cancer Progression.

Authors:  Ailin Zhang; Jiawei Zhang; Stephen Plymate; Elahe A Mostaghel
Journal:  Horm Cancer       Date:  2016-01-21       Impact factor: 3.869

9.  Fatostatin displays high antitumor activity in prostate cancer by blocking SREBP-regulated metabolic pathways and androgen receptor signaling.

Authors:  Xiangyan Li; Yi-Ting Chen; Peizhen Hu; Wen-Chin Huang
Journal:  Mol Cancer Ther       Date:  2014-02-03       Impact factor: 6.261

10.  Cholesterol homeostasis in two commonly used human prostate cancer cell-lines, LNCaP and PC-3.

Authors:  James Robert Krycer; Ika Kristiana; Andrew John Brown
Journal:  PLoS One       Date:  2009-12-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.